author-photo

Jacob D. Soumerai

Harvard University
Memorial Sloan Kettering Cancer Center

83

Papers

1806

Citations

Citation Trend

Filter By

Papers (58) Sort By

Journal Conference Others

Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24)

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.

2020 Blood Cancer Journal
Show All
- Source
- Cite
- Save
Citations (13)
Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

2020 Blood
Show All
- Source
- Cite
- Save
Citations (16)
Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)